An investigation was carried out into the effects of dexrazoxane and doxorubicin on hepatic protein synthesis in vivo. The protocol included 8 groups of rats and involved a pretreatment stage of 30 min followed by a treatment stage of either 2.5 or 24 h. Male Wistar rats ( 0.15-0.20 kg) were pretreated with either dexrazoxan e (100 mg/kg; 5 ml/kg) or saline (0.15 mol/l NaCl; 5 ml/kg). At 30 min after the pretreatment , rats were again injected with either doxorubicin (5 mg/kg; 10 ml/kg) or saline (0.15 mol/l NaCl; 10 ml/kg) in the treatment phase. Rats were sacri ced at either 2.5 or 24 h after the last doxorubicin or saline injection. Rate of protein synthesis were measured 10 min prior to sacri cing rats, with a ooding dose of L-[4-3 H]phenylalanine . Liver was analyzed for the protein synthetic capacity (C s , mg RNA/g protein), the fractional rate of protein synthesis (k s , %/d), and the RNA activity (k RNA mg protein/d/mg RNA). Complementary analysis included plasma albumin, total protein and activities of alkaline phosphatase , and aspartate aminotransferase . In the 2.5-h study, doxorubici n alone had no effect on any of the above variables. Dexrazoxane alone increased C s , k s and k RNA at 2.5 h. Combined dexrazoxan e doxorubicin increased hepatic C S and k s with concomitant reductions in total plasma protein. In the 24-h study, doxorubicin alone had no effect on any of the variables. Dexrazoxan e alone had no effect on either C S , k s , or k RNA but raised plasma activities of alkaline phosphatas e and aspartate aminotransferase. Combined dexrazoxan e doxorubicin increased C s and k s and decreased total plasma protein and increased plasma aspartate aminotransferas e activities at 24 h. In conclusion, there is no evidence that acutely doxorubicin per se has measurable effects on hepatic protein synthesis in vivo in an acute period. However, acutely dexrazoxan e increases hepatic protein synthesis, which may represent its putative cytotoxic effects, as indicated by raised serum activities of liver enzymes. A combination of both dexrazoxane doxorubici n appears to have a greater effect in increasing liver protein synthesis than dexrazoxan e alone.
INTRODUCTION
Although the anthracycline anti-neoplastic antibiotic doxorubicin (ie, doxorubicin has been shown to be a clinically effective anti-cancer agent (for example, in treating lymphoma and leukaemia), its uses are limited due to unwanted side effects that affect a variety of organs. Predominantly, adverse reactions occur in the heart (8), but pathological changes in the liver, kidney, and small intestine have also been reported [for example see (58) ]. These side effects are reported to be due to iron-catalysed free radical formation (2) . Doxorubicin increases the urinary excretion of a number of aldehydes (acetaldehyde, formaldehyde and malondialdehyde) with concomitant increase in hepatic lipid peroxidation (2, 36) .
With respect to the liver, other effects include doxorubicininduced hepatic mRNA induction (6) , nuclei changes (29) , reduction in glutathione (41) , increases in microsomal UDP-glucuronosyltransferase activity (27) , inhibition of oxidative phosphorylation (45) and inhibition of NADPH cytochrome c reductase activities (32) . Overall, there is suf cient evidence to support biochemical mechanisms for doxorubicin-induced hepatotoxicity. However, its effects on protein synthesis have either been carried out on isolated tissue preparations or have involved measurement of protein synthesis without consideration of precursor pools (2) .
The pathogenic nature of doxorubicin-induced side effects may be related to reactive oxygen species (ROS)-mediated cytotoxicity (41) . This includes, for example, the generation of hydroxyl ions radicals via metal ions (40) . The involvement of metal ions in doxorubicin toxicity has led to the development of various cytoprotective agents such as the bisdioxopiperazine compound dexrazoxane (ICRF-187) (16, 26, 58) . The assumption in the deployment of cytoprotective agents is that they have little or no effect on normal tissue function. However, clinical studies have shown that use of dexrazoxane induces a number of side effects, such as suppression of the hematopoietic systems, increased plasma bilirubin concentrations and raised amylase and transaminase activities (50, 53) . Additionally, we have shown that the metal chelator D-penicillamine alters tissue protein synthesis by mechanisms that may involve tissue depletion of metals such as copper, iron, and zinc and/or the induction of metalloproteins (37) . It is possible therefore, that dexrazoxane will also alter liver protein synthesis, although this has not been examined.
In the study described here, we address these issues by examining the effects of both doxorubicin and dexrazoxane. We measured protein synthesis in vivo using the ooding dose method and determined the concentrations of serum proteins and activities of circulating liver marker enzymes.
MATERIALS AND METHODS
Dexrazoxane (also called ICRF-187) was obtained from Chiron, UK Ltd (Hare eld, Middlesex, UK) as the hydrochloride salt. Doxorubicin (doxorubicin) was manufactured by Pharmacia (Milton Keynes, Bucks, UK) and was obtained from the Hospital Pharmacy. Both solutions were prepared fresh on the day of use, employing aseptic techniques. The radioisotope for protein synthesis measurements was obtained from Amersham PLC (Amersham Bucks, UK). All other chemicals were obtained from either The Sigma Chemical Company or BDH (both Poole, Dorset, UK) and were of optimum purity.
Treatment of Animals
Male Wistar rats (approximately 100-150 g) were obtained from Harlan Olac (Bicester, Oxon, UK) and kept in a temperature controlled and humidi ed animal house on a 12 h light/12 h dark cycle. Animals were used after 1 week when they weighed approximately 200-250 g body weight (59) . Rats were weight-ranked and divided into the following 8 groups (details in parenthesis indicated the pretreatment and treatment protocols, respectively). There were no fatalities. The experimental design was such that we could examine the independent effects of both dexrazoxane and doxorubicin within an experimental protocol that also investigated the putative protective properties of dexrazoxane on doxorubicin-induced toxicity (59) . A schematic diagram of the experimental design is presented as Figure 1. 2.5 h studies (Figure 1 : top).
[1] Control (saline, 0.5 h saline, 2.5 h) [2] Doxorubicin (saline, 0.5 h doxorubicin, 2.5 h) [3] Dexrazoxane (dexrazoxane, 0.5 h saline, 2.5 h) [4] [5] Control (saline, 0.5 h saline, 24 h) [6] Doxorubicin (saline, 0.5 h doxorubicin, 24 h) [7] Dexrazoxane (dexrazoxane, 0.5 h saline, 24 h) [8] Dexrazoxane doxorubicin (dexrazoxane, 0.5 h doxorubicin 24 h).
The experimental procedure entailed a pretreatment period of 30 minutes followed by a treatment period of either 2.5 or 24 h (see Figure 1 ). For convenience, we have labelled the FIGURE 1.-Schematic diagram of the experimental design showing times of injection. In the 2.5-h study, saline or dexrazoxan e was given 30 minutes before either saline or doxorubicin . The rats were then sacri ced after a further 2.5 h. In the 24-hr study, food (but not water) was withdrawn at the start of the experiment. studies as '2.5 h' and '24 h' although strictly speaking, the exposure to dexrazoxane was 3 and 24.5 h, respectively. The doses were as follows: dexrazoxane, 100 mg/kg body weight, IP; doxorubicin, 5 mg/kg body weight, IP; saline, 0.15 mol/l NaCl, IP. These doses of dexrazoxane are within the recommended ratios of doxorubicin: dexrazoxane of 1:20 (21) and previously used dosage regimens within the reported nontoxic dose range of 50-250 mg/kg body weight in small laboratory rodents (20) . In the pretreatment phase, saline or dexrazoxane was delivered in a volume of 5 ml/kg body weight, IP. In the treatment phase, saline or doxorubicin was delivered in a volume of 10 ml/kg body weight, IP. At the end of the study, rats were sacri ced by decapitation for collection of blood and extraction of plasma at 4 C. In the rats treated for 2.5 h, animals were injected from 8 am-4 pm and were effectively postabsorptive as rats consume most of their diet during the night. In rats treated for 24 h (groups 5-7), food was withdrawn after the last injection of either saline or doxorubicin to circumvent any in uence of treatment-induced weight gain on hepatic protein synthesis (reported for both doxorubicin and dexrazoxane (4). Thus, any effects from the treatment protocols were not due to differences in food intake (59).
Our method of measuring protein synthesis does not require any manipulation or use of other such treatments known to alter protein synthesis [see (38) ]. In this method, the isotope has to be injected into the lateral tail vein to avoid surgery or anaesthesia. Due to the toxicity of the agents under investigation, we thought it more prudent to inject both doxorubicin and dexrazoxane IP in case there was damage to the lateral tail vein that might have impeded the subsequent injection of the radiolabelled phenylalanine along this route. The administration of dexrazoxane in rats by the IP route has been reported previously (18, 51) as has doxorubicin (24, 28, 35) .
Methods for Measuring Protein Synthesis
To measure protein synthesis rates in vivo, rats were given a ooding dose of L- [4- 3 H] phenylalanine (150 l mol/100 g body weight) through a lateral tail vein (9) . At 10 min after injection of the isotope, rats were sacri ced and the livers removed and immersed in liquid nitrogen (9) .
Processing of liver for phenylalanine speci c radioactivities including homogenisation were carried out at 0-4 C unless otherwise stated. Livers were brie y homogenised in distilled water and precipitated with perchloric acid to a nal concentration of 0.2 mol/l. After centrifugation (all centrifugation steps between 1,500-2,000 g, 15-20 mins, 4 C), the acid supernatants of mixed hepatic homogenates were decanted and neutralised with saturated tripotassium citrate to obtain S i , the speci c radioactivity of free phenylalanine in liver. Protein pellets were repeatedly washed 6 to 8 times in 10-14 ml of 0.2 mol/l perchloric acid. The washing consisted of suspending the liver protein in fresh 0.2 mol/l perchloric acid with frequent and thorough mixing followed by centrifugation and aspiration of the supernatant to waste. After the nal wash, protein pellets were hydrolysed in 6 mol/l HCl for 36 h at 105 C (9).
The hydrolysates of liver proteins were dried in vacuo and the residues were suspended in sodium citrate buffer (pH 6.3, 1.5 mol/l). The suspension was incubated with phenylalanine decarboxylase, (49-52 C; 24 h) to convert phenylalanine to b -phenylethylamine. The b -phenylethylamine was then isolated by a series of solvent and aqueous extractions (9) . Neutralised extracts of acid supernatants of liver homogenates (ie, containing S i ) were similarly treated with phenylalanine decarboxylase.
To obtain speci c radioactivities, that is, dpm /nmol b -phenylethylamine equivalent to dpm /nmol phenylalanine before enzymatic incubation, acidi ed extracts of b -phenylethylamine were assayed by uorimetry and scintillation radio-spectrophotometry (9) .
Measurement of Liver Composition and Plasma Analytes
The biuret method was used for determining protein (10) . RNA determinations were made using a 2-wavelength, ultraviolet (UV) spectrophotometric method (33) . Plasma analytes (aspartate aminotransferase, alkaline phosphatase, total protein, and albumin) were assayed as previously described (46, 47) .
Calculation of Synthesis Rates
Fractional rates of protein synthesis, de ned as the percentage of liver protein renewed each day, ie, %/d, was calculated from the formula: k S (S b 100)/(S i t); where: S b is the speci c radioactivity of phenylalanine incorporated into liver protein (dpm /nmol); S i is the speci c radioactivity of free phenylalanine in acid soluble fractions of liver homogenates (dpm /nmol); t is the period of time (in days) between injection of the isotope and immersion of liver in liquid nitrogen.
Other synthesis measurements include the RNA activity ( k RNA, mg protein /d/ mg RNA), which describes in dynamic terms the synthesis rate per unit ribosome. It is based on the observation that most RNA is ribosomal and there is a strong correlation between ribosomal content and fractional synthesis rates (39) .
Statistics
All data are means SEM (n 5-8). Statistical analysis was performed by using the method of least squares for multiple comparisons. Signi cance was assumed when p was equal to, or less than, 0.05. NS, not signi cant.
RESULTS
In the ensuing description of the results, we rst describe the actions of doxorubicin, followed by the effects of dexrazoxane, then the combined effects of the two agents.
Doxorubicin
At both the 2.5-and 24-h time points, there was no measurable effect of doxorubicin on any of the parameters of protein synthesis in liver (Figures 2 and 3) . Plasma analytes were also unaffected by doxorubicin (Figures 4-7) .
Dexrazoxane
In the 2.5-h studies, exposure to IRCF-187 alone increased C s ( 7%, p < 0.05), k s ( 24%, p < 0.001) and k RNA ( 16%, p < 0.001; Figure 2) . None of the plasma analytes were altered at 2.5 h (Figures 4 and 5) . In 24 h-dosed rats, dexrazoxane alone had no effect on any of the indices of protein synthesis (Figure 3) . However, at 24 h, increased plasma activities of both alkaline phosphatase and aspartate aminotransferase occurred (both 33%, p < 0.05 compared to controls ( Figure 6 ).
Dexrazoxane Doxorubicin
In the 2.5-h study, rats treated with both dexrazoxane doxorubicin had increased k s ( 15%, p < 0.025) and k RNA ( 12%, p < 0.05; Figure 2 ). Total plasma protein was reduced slightly by dexrazoxane doxorubicin at 2.5 h ( 8%, p < 0.05) but this change was not due to perturbations in albumin levels ( Figure 5 ).
In the 24-h study, dexrazoxane doxorubicin increased C s ( 8%, p < 0.025) and k s ( 17%, p < 0.01; Figure 3) . As with the 2.5-h study, total plasma protein was reduced slightly by dexrazoxane doxorubicin at 24 h ( 7%, p < 0.05) though albumin was unaffected (Figure 7) . At 24 h, increased plasma activities of aspartate aminotransferase occurred ( 47%, p < 0.001 compared to controls; Figure 6 ).
The activities of alkaline phosphatase in plasma of 24-h rats s treated with either dexrazoxane (ie, 286 47 IU/l) or dexrazoxane doxorubicin (226 15 IU/l) were actually similar to activities at 2.5 h (268 17 IU/l and 229 12 IU/l, for FIGURE 2.-Liver protein synthetic capacity (Cs, mg RNA/g protein), fractional rates of protein synthesis (k s , %/d) and RNA activities (k RNA , mg protein /d /mg RNA) in rats treated with doxorubicin and dexrazoxane for rats treated for 2.5 h. The data are expressed as mean SEM, where (n) is the number of observations . In the 2.5-h study, saline or dexrazoxan e was given 30 minutes before either saline or doxorubicin . The rats were then sacri ced after a further 2.5 h. The treatments for the 24-h study were similar to the 2.5-h study. Saline or dexrazoxan e was given 30 minutes before either saline or doxorubicin, but the rats were sacri ced after a further 24 h. The differences between the control group and other groups were assessed by Student's t-test using the pooled estimate of variance. Levels of signi cance were concluded when p was less than or equal to 0.05 and are displayed over the histograms. dexrazoxane and dexrazoxane doxorubicin groups, respectively). However, alkaline phosphatase activities in the saline controls at 2.5 h were 291 22 IU/l compared to 215 16 IU/l in the 24-h group. Thus, dexrazoxane may have actually inhibited the fasting-induced decrease in enzyme activities. 
DISCUSSION
It was our hypothesis that many of the cytotoxic effects of doxorubicin on the liver may be re ected by pathogenic alterations in protein synthesis in vivo. This would have important implications for protein nutrition because of the liver's contribution (about 15-25%) to whole-body protein synthesis and the pivotal role of this organ in the synthesis of plasma protein such as albumin. In the present studies, there was no effect of doxorubicin on liver C s , k s or k RNA and we must therefore concur that it has little effect as a protein synthetic perturbant in this tissue. Some cytotoxic effects of doxorubicin have been reported in response to chronic dosing regimens. However, it is important to emphasise that when doxorubicin is given in single dose, cytotoxicity is reported to occur [as determined by a number of variables, for example see (2, 6, 41) ]. It is possible that the dosage regimen of doxorubicin in the present study (5 mg/kg) was inappropriate, but this can be refuted as identical or lower doses have been reported to cause a variety of biochemical or pathological reactions (19, 42, 55, 56) .
One of the surprising observations of this study was a reduction in plasma proteins when both doxorubicin and dexrazoxane were administered together, consistent with a synergistic effect. The reason the total plasma protein concentration fell in dexrazoxane doxorubicin treated rats at 24 h is not clear, but the lack of change of plasma albumin indicates that the globulin fraction was perturbed. The increases in C s and k s in rats dosed with dexrazoxane doxorubicin at 24 h is further evidence for a synergistic effect. This effect was not seen in rats dosed with doxorubicin or dexrazoxane alone in the 24-h study. There is evidence in the literature that under certain circumstances, doxorubicin and dexrazoxane may act synergistically. In HL-60 cells, doxorubicin-induce d cytotoxicity is potentiated by dexrazoxane (30) . In vivo, weight reductions induced by a combination of dexrazoxane doxorubicin is greater than either dexrazoxane or doxorubicin FIGURE 6.-Plasma alkaline phosphatas e and aspartate aminotransferas e activities, in rats treated with doxorubici n and dexrazoxane for 24 h. alone, even though the combination of these agents conferred cardioprotection compared to doxorubicin alone (54) . In Chinese hamster ovary cells, a combination of dexrazoxane and low-dose of doxorubicin results in greater inhibition of growth compared to dexrazoxane or doxorubicin alone (17) .
We hypothesised that dexrazoxane would alter hepatic protein synthesis, perhaps because of its chelating properties (37) . The ring ring-opening hydrolysis of the chirally structured dexrazoxane, by the enzyme dihydropyrimidine amidohydrolase, occurs in the liver (14) . The hydrolysis product of ICRF-159 (ie, DL-N,N -dicarboxamidomethyl-N,Ndiacarboxymethyl-1,2-diamino propane; ICRF-198, ADR-925) has an EDTA structure and chelates metals such as copper, iron, and zinc, which may alter normal homeostatic mechanisms (57) . The binding of iron may also provide the basis for the therapeutic application of dexrazoxane, by ameliorating iron-catalysed generation of reactive oxygen species (11) . However, ferric complexes of ADR-925 are able to generate hydroxyl radicals (12) . The possibility that the parent compound may increase oxidative stress has been obtained from analysis of kidney in rats treated with dexrazoxane that show increased concentrations of malondialdehyde and thiobarbituric acid-reactive substances after cumulative dosage (58) .
The supposition that dexrazoxane was a metabolic perturbant was substantiated in the 2.5-h studies, which showed that administration of this compound alone altered protein synthesis, although this effect was not apparent in 24-h treated rats. The pharmacokinetics of dexrazoxane in the rat have been published and its short half-life and rapid elimination (14, 22) may help to explain why at 24 h, we see no signi cant effect of dexrazoxane alone on any of the protein synthesis parameters, whereas at 2.5-h study, it increases C s , k s , and k RNA .
In 24-h-dosed rats, there were increases in the plasma activities of the marker enzymes alkaline phosphatase and aspartate aminotransferase indicative of hepatic damage in response to dexrazoxane. In the rat (but not in man), alkaline phosphatase has been reported to be derived largely from the gastrointestinal tract and its diagnostic use in identifying liver pathologies may not be reliable (25) . However, we are condent that dexrazoxane alone caused some degree of liver damage as aspartate aminotransferase activities, which are derived predominantly from the liver, also increased in 24-h dexrazoxane-dosed rats. These data are, however, contrary to a previous study, which reported that dexrazoxane ameliorates acetaminophen-induced increases in alkaline phosphatase (5) . Nevertheless, our data in rats is consistent with the reported increase in aminotransaminase activities in patients treated with dexrazoxane (53) .
The speci c mechanisms whereby dexrazoxane increased rates of protein metabolism in the liver are unclear. The increase in protein synthesis may be related to up-regulation of hepatic proteins such as the transferrin receptor (52) . Effects of dexrazoxane on cell nuclei cannot be ruled out as it inhibits the activity and amount of both a -and b -isoforms of the nuclear and mitochondrial located enzyme DNA topoisomerase II (7, 43) . This effect on topoisomerase II is ATPdependent and has been proposed as a mechanism for dexrazoxane cytoprotectivity (43) . More detailed cell studies have shown that dexrazoxane inhibits chromosome condensation, perturbs the distribution and structure of chromosomes, and impedes the separation of centromeres in anaphase with an overall effect on mitosis (1). Apoptosis is also increased by dexrazoxane in human leukemic CEM/VM-1 cells possibly via increased caspase-3 and -7 activity (23). The growth of Chinese hamster ovary cells is reduced by dexrazoxane by a mechanism that may be linked to inhibition of topoisomerase II activity (15) . Although the hydrolysis product of dexrazoxane, ADR-925, is able to generate hydroxyl radicals, it does not inhibit the growth of Chinese hamster ovary cells or inhibit topoisomerase II activity (12) . Overall, one might expect these processes to reduce liver protein synthesis in vivo, but the opposite occurred in dexrazoxane-treated rats. The increased protein synthesis may therefore re ect a compensatory adaptation, or an up-regulation of hepatic proteins as yet unidenti ed. Certainly, at the whole-body level, dexrazoxane reduces animal growth in vivo (54) and the increased metabolic demands, imposed by elevated protein synthesis, may contribute to this. For example, cachetic states such as sepsis are characterised by elevated rates of hepatic protein synthesis; ie, see ref (34) .
A variety of earlier studies on cell lines have suggested that dexrazoxane may modulate protein and RNA synthesis and these have been supported by more recent experiments (13, 31, 52) . However, our study differs in that this is the rst study to examine this agent with respect to its ability to modulate protein synthesis in vivo using reliable methods that take into account amino-acyl tRNA charging (3) .
It is important to reiterate that, although the doses we used were comparable to other studies in which dexrazoxane and doxorubicin were administered, they are in fact higher than the doses used clinically (for examples of clinical doses see (44, 48, 49) ). However, consideration needs to be given to the fact that we employed the recommended ratio of doxorubicin:dexrazoxan e of 1:20 (21) and previously used dosage regimens within the reported nontoxic dose range of 50-250 mg/kg body weight in small laboratory rodents (20) .
In these studies, we used only a single dose level of dexrazoxane and doxorubicin, although consideration needs to be given to the fact that both these agents impart dose-dependent changes. For example, the growth inhibition by dexrazoxane in the rat is dose-dependent (54) . In our studies, dexrazoxane is used acutely to show to altered protein synthesis, whereas in practical terms it is used chronically to reduce doxorubicin toxicity. Nevertheless, the primary objective was to determine the hepatotoxicity of these agents with respect to protein metabolism and in particular protein synthesis in vivo, a supposition con rmed by the conclusion that a single dose of dexrazoxane increases [ 3 H]-phenylalanine incorporation in the liver and raises plasma activities of marker enzymes.
